PLSE logo

PLSE
Pulse Biosciences Inc

2,047
Mkt Cap
$1.3B
Volume
169,487.00
52W High
$26.30
52W Low
$12.56
PE Ratio
-17.82
PLSE Fundamentals
Price
$19.25
Prev Close
$19.06
Open
$18.72
50D MA
$20.17
Beta
1.39
Avg. Volume
261,776.74
EPS (Annual)
-$1.08
P/B
16.19
Rev/Employee
$3,017.24
$852.13
Loading...
Loading...
News
all
press releases
Pulse Biosciences Appoints Liane Teplitsky CCO, Expands David Kenigsberg Role As Full Time CMO
(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, Thursday, announced the appointment of Liane Teplitsky as Chief Operating Officer...
Nasdaq News: Markets·21h ago
News Placeholder
More News
News Placeholder
Pulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced the strengthening of its executive leadership...
Business Wire·21h ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 11.7% - Here's Why
Pulse Biosciences (NASDAQ:PLSE) Trading Down 11.7% - Here's Why...
MarketBeat·3d ago
News Placeholder
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced enrollment of the first patients in its...
Business Wire·3d ago
News Placeholder
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA), today announced plans to present at the upcoming 25th Annual...
Business Wire·8d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 7% - Here's What Happened...
MarketBeat·11d ago
News Placeholder
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
Zacks·15d ago
News Placeholder
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study
Pulse Biosciences (NASDAQ:PLSE) executives highlighted recent clinical results for the company's nanosecond pulsed field ablation (nsPFA) technology, outlined plans for a U.S. investigational device...
MarketBeat·20d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving Average - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened...
MarketBeat·23d ago
News Placeholder
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA), today announced a new strategic alignment to prioritize and...
Business Wire·24d ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.